Cargando…
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), c...
Autores principales: | Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742629/ https://www.ncbi.nlm.nih.gov/pubmed/26771810 http://dx.doi.org/10.1038/bcj.2015.112 |
Ejemplares similares
-
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021) -
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013) -
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)